Clinical Trials
12
Active:0
Completed:8
Trial Phases
3 Phases
Phase 1:6
Phase 2:5
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (50.0%)Phase 2
5 (41.7%)Phase 3
1 (8.3%)QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1
Terminated
- Conditions
- Lung CancerPancreatic CancerThyroid CancerOvarian CancerBreast CancerColon Cancer
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03127098
- Locations
- 🇺🇸
Medical Oncology Associates, Spokane, Washington, United States
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
Phase 2
Completed
- Conditions
- Chordoma
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02383498
- Locations
- 🇺🇸
NIH Clinical Center, Bethesda, Maryland, United States
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Phase 2
Completed
- Conditions
- Medullary Thyroid Cancer (MTC)
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT01856920
- Locations
- 🇺🇸
NIH Clinical Center, Bethesda, Maryland, United States
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Phase 3
Completed
- Conditions
- Adenocarcinoma of the PancreasAdvanced Solid TumorsCancerCancer of PancreasMetastatic Pancreatic CancerPancreas CancerCancer of the PancreasMetastasesMetastatic CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT01231347
- Locations
- 🇬🇧
Research Site, Northampton, United Kingdom
QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsCancerSolid TumorsTumorsAdvanced Malignancy
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00974896
- Prev
- 1
- 2
- 3
- Next
News
No news found